Distinct cellular mechanisms underlie chemotherapies and PD-L1 blockade combinations in triple-negative breast cancer
Zhang et al. investigate immune cell dynamics in TNBC patients treated with paclitaxel, nab-paclitaxel, and combinations with atezolizumab. They identify distinct underlying cellular mechanisms, revealing that nab-paclitaxel induces mast cell expansion, associated with increased lymphocyte infiltration. Mast cell activation may represent a promising strategy to enhance anti-PD-L1 efficacy in TNBC.
